The key to achieving robust analytical results lies in the combination of sensitivity, selectivity, and specificity. Recent technological advancements enable the most demanding sample types and workflows.
Collecting quality MS/MS at high acquisition rates is key to achieving high numbers of peptide and protein identifications. This study investigates the impact of large sensitivity gain on identification rates.
A model of human IBD has been established to enable the screening and detailed characterization of novel therapeutic agents combining measures that bridge non-invasive and high-throughput testing with clinically relevant endpoints of this disease.